2023 APRIL

Transporters and pharmacogenetics

Clin Pharmacol Ther. 2023;113:782-793. PharmVar GeneFocus: SLCO1B1. Ramsey LB, Gong L, Lee SB, Wagner JB, Zhou X, Sangkuhl K, Adams SM, Straka RJ, Empey PE, Boone EC, Klein TE, Niemi M, Gaedigk A. PubMed

Expert Opin Drug Metab Toxicol. 2023;In press. Genetic variation in organic cation transporters and considerations in drug development. Varma MVS. PubMed

Experimental models

Clin Pharmacol Ther. 2023;In press. 3D spheroid primary human hepatocytes for prediction of cytochrome P450 and drug transporter induction. Järvinen E, Hammer HS, Pötz O, Ingelman-Sundberg M, Stage TB. PubMed

Clin Pharmacol Ther. 2023;In press. Novel explanted human liver model to assess hepatic extraction, biliary excretion, and transporter function. Stevens LJ, Dubbeld J, Doppenberg JB, van Hoek B, Menke AL, Donkers JM, Alsharaa A, de Vries A, Vaes WHJ, Knibbe CAJ, van de Steeg E, Alwayn IPJ. PubMed

Nat Rev Gastroenterol Hepatol. 2023;20:269 Human hepatocyte organoids model in early NAFLD. Hindson J. PubMed

J Hepatol. 2023;In press. A human liver organoid screening platform for DILI risk prediction. Zhang CJ, Meyer SR, O'Meara MJ, Huang S, Capeling MM, Ferrer-Torres D, Childs CJ, Spence JR, Fontana RJ, Sexton JZ. PubMed

Transporters and PBPK in liver disease

Clin Pharmacol Ther. 2023;In press. Dose adjustment in patients with liver cirrhosis - comparison of two different modeling approaches. Ozbey AC, Bachmann F, Duthaler U, Annaert P, Fowler S, Umehara K, Parrott N, Krähenbühl S. PubMed

Clin Pharmacol Ther. 2023;113:1058-1069. Effect of hepatic impairment on OATP1B activity: Quantitative pharmacokinetic analysis of endogenous biomarker and substrate drugs. Lin J, Kimoto E, Yamazaki S, Vourvahis M, Bergman A, Rodrigues AD, Costales C, Li R, Varma MVS. PubMed

Clin Pharmacol Ther. 2023;In press. Effect of chronic hepatitis C on the activity of the membrane transporters P-gp and OATP1B1/BCRP on patients with different stages of hepatic fibrosis. Pippa LF, Vieira CP, Caris JA, Rocha A, Marques MP, Garcia CP, Rezende REF, Lanchote VL. PubMed

Acta Pharm Sin B. 2023;13:1-28. Predicting disruptions to drug pharmacokinetics and the risk of adverse drug reactions in non-alcoholic steatohepatitis patients. Marie S, Frost KL, Hau RK, Martinez-Guerrero L, Izu JM, Myers CM, Wright SH, Cherrington NJ. PubMed

Hepatic clearance

Drug Metab Dispos. 2023;51:618-628. Exploring the pharmacokinetic mysteries of the liver: Application of series compartment models of hepatic elimination. Li X, Jusko WJ. PubMed

AAPS J. 2023;25:40. In vitro-in vivo extrapolation and scaling factors for clearance of human and preclinical species with liver microsomes and hepatocytes. Tess D, Chang GC, Keefer C, Carlo A, Jones R, Di L. PubMed

Pharm Res. 2023;40:937-949. Simplifying the Extended Clearance Concept Classification System (EC3S) to guide clearance prediction in drug discovery. Patel M, Riede J, Bednarczyk D, Poller B, Deshmukh SV. PubMed

Transporters and cryopreservation

Toxicol in vitro. 2023; In press. Drug transporter expression and activity in cryopreserved human hepatocytes isolated from chimeric TK-NOG mice with humanized livers. Zerdoug A, Le Vée M, Uehara S, Jamin A, Higuchi Y, Yoneda N, Lopez B, Chesné C, Suemizu H, Fardel O. PubMed

Regulation of OATP1B3

Pharmaceutics. 2023;15:738. Transcriptional regulation of liver-type OATP1B3 (Lt-OATP1B3) and cancer-type OATP1B3 (Ct-OATP1B3) studied in hepatocyte-derived and colon cancer-derived cell lines. Haberkorn B, Löwen D, Meier L, Fromm MF, König J. PubMed

Drug-induced cholestasis

Int J Mol Sci. 2023;24:5823. Molecular and clinical links between drug-induced cholestasis and familial intrahepatic cholestasis. Vitale G, Mattiaccio A, Conti A, Berardi S, Vero V, Turco L, Seri M, Morelli MC. PubMed